{"retracted":true,"timestamp":1451606400000,"update":{"timestamp":null,"doi":null,"pmid":26732311,"type":"retraction"},"doi":"10.2217/cns.15.38","journal":"CNS oncology","publisher":null,"title":"ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma."}
